Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. NOW
3. TSLA
4. TXN
5. GOOG
6. IBM
7. LVS
8. INTC
9. RJF
10. KNX

Go back to Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
ENANTA PHARM (NASDAQ: ENTA) Delayed: 13.06 --0 (-0%)
Previous Close $13.06    52 Week High $34.49 
Open $13.06    52 Week Low $20.39 
Day High $13.06    P/E N/A 
Day Low $13.06    EPS $-3.18 
Volume 1,352